Publications by authors named "N Andratschke"
The PRIMALung EORTC-1901 trial investigates brain MRI ± PCI in all-stages of SCLC, aiming for non-inferior survival, improve cognition in the era of immunotherapy. @finn_corinne.
View Article and Find Full Text PDFIntroduction: Reirradiation has gained increasing interest, as advances in systemic therapy increase the survival of patients with cancer, and modern radiation techniques allow more precise treatments. However, high-quality prospective evidence on the safety and efficacy of reirradiation to guide clinical practice remains scarce. This systematic review evaluates ongoing prospective studies on reirradiation to identify research gaps and priorities.
View Article and Find Full Text PDFBackground/purpose: High doses to healthy cardiac substructures (CS) in stereotactic arrhythmia radioablation (STAR) raise concerns regarding potential treatment-induced cardio-toxicity. However, CS contours are not routinely created, hindering the understanding of the CS dose-effect relationships. To address this issue, the alignment of CS contouring was initiated within the STOPSTORM consortium.
View Article and Find Full Text PDFArticle Synopsis
- A subgroup of patients with oligometastatic cancer may benefit from local treatment of all cancer lesions to achieve longer disease-free survival, especially when brain metastases are involved.
- An analysis of 7,000 PET scans identified 106 patients with both extracranial oligometastases and brain metastases, finding that brain involvement significantly impacted disease classification and treatment outcomes.
- Patients with oligometastasic disease had a median survival of 28 months compared to 10 months for polymetastatic patients, suggesting that brain metastases should not automatically exclude individuals from clinical trials.
With the emergence of high-precision radiotherapy technologies such as stereotactic ablative radiotherapy (SABR), MR guided brachytherapy, image guided intensity modulated photon and proton radiotherapy and most recently daily adaptive radiotherapy, reirradiation is increasingly recognized as a viable treatment option for many patients. This includes those with recurrent, metastatic or new malignancies post initial radiotherapy. The primary challenge in reirradiation lies in balancing tumor control against the risk of severe toxicity from cumulative radiation doses to previously irradiated normal tissue.
View Article and Find Full Text PDF